Genome & Company
Daily close in US$ at the latest USD/KRW close. Source: KRX via FinanceDataReader.
Genome&Company is a drug-discovery company that develops experimental cancer treatments, including antibody-drug conjugates (ADCs, which attach a toxic payload to an antibody to target tumour cells) and immune-oncology therapies that help the immune system attack cancer.
It operates on KOSDAQ, South Korea's tech and small-cap exchange. Its core business model is to discover and develop drug candidates using its proprietary GNOCLE™ platform, then license the resulting technology to other pharmaceutical companies rather than advancing drugs to market itself.
Summary is AI-generated and may contain errors · figures from DART filings
The company has completed technology-transfer deals with Ellipses Pharma Limited and Debiopharm, licensing out two separate novel-target programmes to those named global partners.
Genome & Company in five facts
What does Genome & Company do?
Genome&Company is a drug-discovery company that develops experimental cancer treatments, including antibody-drug conjugates (ADCs, which attach a toxic payload to an antibody to target tumour cells) and immune-oncology therapies that help the immune system attack cancer.
Where is Genome & Company listed and in which sector?
Genome & Company (Korean name: 지놈앤컴퍼니) trades under KRX code 314130 on KOSDAQ, the Korea Exchange's board for smaller and growth companies. It is classified in the Health Care sector, Pharmaceuticals.
How large is Genome & Company?
Its market capitalisation was US$166.6M on 2026-10-21, which puts it in this site's small-cap group. US$ amounts are converted from won at 1 USD ≈ ₩1,325 (2026-10-21).
What were Genome & Company's latest annual revenue and operating profit?
For fiscal year 2025, Genome & Company reported revenue of US$18.6M, an operating loss of US$22.1M and a net loss of US$5.8M, per its annual report on DART (data retrieved from DART on 2026-10-02). Revenue was down 11.4% on the previous year.
Where does this data come from?
Financial statements and filings come from DART, Korea's official corporate-filing system. Share prices, market capitalisation and trading status come from KRX. Company summaries are AI-generated from the filings and may contain errors; financial figures are mapped directly from DART.
Data sources and last updated
- Filings and financial statements
- DART (dart.fss.or.kr), Korea's official corporate-filing system
- Prices, market cap, trading status
- KRX (Korea Exchange), via FinanceDataReader
- Latest annual financials
- Fiscal year 2025, data retrieved from DART on 2026-10-02
- Share price and market cap
- Close of 2026-10-21
- Currency
- US$, converted from won at 1 USD ≈ ₩1,325 (2026-10-21 close)
- Company data updated
- 2026-10-21
- Company summary
- AI-generated from filings; may contain errors. Information only, not investment advice.
- Conversion price adjustmentOct 13
- Other management matter (voluntary)Oct 7
- Early redemption of convertible bonds (incl. overseas CBs)Capital raise · Oct 7
- Investor relations (IR) meetingSep 29
- Early redemption of convertible bonds (incl. overseas CBs)Capital raise · Apr 7
- Material event report (rights offering)
Genome & Company disclosed a private placement (third-party allotment) to raise US$4.64M, about 2.3% of its market value.
Capital raise · Apr 3 - Material event report (rights offering)
Genome & Company disclosed a private placement (third-party allotment) to raise US$2.03M, about 1.0% of its market value.
Capital raise · Mar 6 - Material event report (convertible bonds)
Genome & Company disclosed convertible bonds to raise US$18.2M, about 9.0% of its market value.
Capital raise · Mar 6 - Change of 30% or more in revenue or profit/loss structure (15% for large companies)
Genome & Company reported consolidated results for FY2025: revenue of US$17M (−11.4% year on year), an operating loss of US$20.3M and a net loss of US$5.81M.
Earnings · Feb 23 - Early redemption of convertible bonds (incl. overseas CBs)Capital raise · Jan 7